EPHA3 and central nervous system cancer: When orthotopic glioma-bearing rats were used to test the anti-glioma effectiveness in vivo, the results showed that anti-EphA3-TMZ@AuNPs significantly boosted tumor-cell apoptosis compared to TMZ and extended the median survival period to 42 days, affirming it as an efficient intranasal drug delivery stratagem for the treatment of GBM [87].